GRI BIO, Inc. Files 8-K for Other Events
Ticker: GRI · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1824293
Sentiment: neutral
Topics: 8-K, corporate-update, filing
TL;DR
GRI BIO (formerly Vallon Pharma) filed an 8-K on 7/19. Standard update.
AI Summary
GRI BIO, Inc. filed an 8-K on July 19, 2024, to report other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. until September 10, 2020, is based in La Jolla, California.
Why It Matters
This filing indicates GRI BIO, Inc. is providing updates on its corporate activities and financial status to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine filing for a public company and does not appear to contain any immediately alarming information.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing with the SEC)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- 20200910 (date) — Date of name change
- July 19, 2024 (date) — Date of report
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by GRI BIO, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
When did GRI BIO, Inc. change its name from Vallon Pharmaceuticals, Inc.?
The date of the name change from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc. was September 10, 2020.
What is the principal executive office address for GRI BIO, Inc.?
The principal executive offices are located at 2223 Avenida de la Playa, #208, La Jolla, CA 92037.
What is the SEC file number for GRI BIO, Inc.?
The SEC file number for GRI BIO, Inc. is 001-40034.
What is the IRS Employer Identification Number for GRI BIO, Inc.?
The IRS Employer Identification Number for GRI BIO, Inc. is 82-4369909.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-07-19 16:03:19
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
- $1,038,886 — s Agreement"), to up to an aggregate of $1,038,886 of Shares, which does not include the S
- $961,272 — gate gross sales price of approximately $961,272 that have been sold to date under the S
Filing Documents
- val-20240719.htm (8-K) — 24KB
- ex51_mintzopinion.htm (EX-5.1) — 14KB
- mintzlogo.jpg (GRAPHIC) — 6KB
- picture1.jpg (GRAPHIC) — 4KB
- val-20240719_g1.jpg (GRAPHIC) — 16KB
- val-20240719_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000084.txt ( ) — 209KB
- val-20240719.xsd (EX-101.SCH) — 2KB
- val-20240719_lab.xml (EX-101.LAB) — 23KB
- val-20240719_pre.xml (EX-101.PRE) — 13KB
- val-20240719_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 19, 2024, GRI Bio, Inc. (the "Company") filed a prospectus supplement to increase the maximum number of shares (the "Shares") of the Company's common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the "Sales Agreement"), to up to an aggregate of $1,038,886 of Shares, which does not include the Shares having an aggregate gross sales price of approximately $961,272 that have been sold to date under the Sales Agreement. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Shares.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 23.1 Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 19, 2024 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer